Roland Haubner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4629252/publications.pdf

Version: 2024-02-01

47 papers

5,224 citations

32 h-index 233421 45 g-index

47 all docs

47 docs citations

47 times ranked

4443 citing authors

#	Article	IF	Citations
1	Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology. Pharmaceuticals, 2020, 13, 22.	3.8	30
2	Comparison of 68Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold. Nuclear Medicine and Biology, 2019, 78-79, 1-10.	0.6	17
3	DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. Journal of Nuclear Medicine, 2019, 60, 1010-1016.	5.0	36
4	[68Ga]NOTA-Galactosyl Human Serum Albumin: a Tracer for Liver Function Imaging with Improved Stability. Molecular Imaging and Biology, 2017, 19, 723-730.	2.6	11
5	Sulfonation of Tyrosine as a Method To Improve Biodistribution of Peptide-Based Radiotracers: Novel ¹⁸ F-Labeled Cyclic RGD Analogues. Molecular Pharmaceutics, 2017, 14, 1169-1180.	4.6	8
6	PET and SPECT. , 2017, , 361-402.		1
7	[68Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2005-2013.	6.4	38
8	Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [68Ga]NODAGA-RGD—In Vivo Imaging Studies in Human Xenograft Tumors. Molecular Imaging and Biology, 2016, 18, 758-767.	2.6	17
9	Fusarinine C, a novel siderophoreâ€based bifunctional chelator for radiolabeling with Galliumâ€68. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 209-214.	1.0	31
10	[68Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold—synthesis and evaluation. Nuclear Medicine and Biology, 2015, 42, 115-122.	0.6	50
11	Novel Bifunctional Cyclic Chelator for 89Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates. Molecular Pharmaceutics, 2015, 12, 2142-2150.	4.6	70
12	Recent Trends in Pharmaceutical Radiochemistry for Molecular PET Imaging. BioMed Research International, 2014, 2014, 1-3.	1.9	1
13	H-CRRETAWAC-OH, a Lead Structure for the Development of Radiotracer Targeting Integrin <i>α </i> _{ 5 } <i> i> ² </i> _{ 1 } ?. BioMed Research International, 2014, 2014, 1-12.	1.9	12
14	PET Radiopharmaceuticals for Imaging Integrin Expression: Tracers in Clinical Studies and Recent Developments. BioMed Research International, 2014, 2014, 1-17.	1.9	65
15	In Vivo Monitoring of the Antiangiogenic Effect of Neurotensin Receptor-Mediated Radiotherapy by Small-Animal Positron Emission Tomography: A Pilot Study. Pharmaceuticals, 2014, 7, 464-481.	3.8	18
16	¹⁸ F-Glyco-RGD Peptides for PET Imaging of Integrin Expression: Efficient Radiosynthesis by Click Chemistry and Modulation of Biodistribution by Glycosylation. Molecular Pharmaceutics, 2014, 11, 505-515.	4.6	73
17	[68Ga]NS3-RGD and [68Ga] Oxo-DO3A-RGD for imaging $\hat{l}\pm v\hat{l}^2$ 3 integrin expression: synthesis, evaluation, and comparison. Nuclear Medicine and Biology, 2013, 40, 65-72.	0.6	19
18	Development of 68Ga-labelled DTPA galactosyl human serum albumin for liver function imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1245-1255.	6.4	31

#	Article	IF	CITATIONS
19	Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. Nuclear Medicine Communications, 2011, 32, 887-895.	1.1	33
20	[68Ga]NODAGA-RGD for imaging $\hat{l}\pm\nu\hat{l}^2$ 3 integrin expression. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1303-1312.	6.4	111
21	Novel ⁶⁴ Cu- and ⁶⁸ Ga-Labeled RGD Conjugates Show Improved PET Imaging of α _ν β ₃ Integrin Expression and Facile Radiosynthesis. Journal of Nuclear Medicine, 2011, 52, 1276-1284.	5.0	141
22	Radiotracer II: Peptide-Based Radiopharmaceuticals., 2011,, 247-266.		1
23	Positron emission tomography tracers for imaging angiogenesis. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 86-103.	6.4	102
24	Labeling and Glycosylation of Peptides Using Click Chemistry: A General Approach to $\langle \sup 18 \langle \sup Fa \in G \text{Glycopeptides}$ as Effective Imaging Probes for Positron Emission Tomography. Angewandte Chemie - International Edition, 2010, 49, 976-979.	13.8	109
25	PET radiopharmaceuticals in radiation treatment planning – Synthesis and biological characteristics. Radiotherapy and Oncology, 2010, 96, 280-287.	0.6	46
26	Derivation of a Compartmental Model for Quantifying 64Cu-DOTA-RGD Kinetics in Tumor-Bearing Mice. Journal of Nuclear Medicine, 2009, 50, 250-258.	5.0	33
27	Noninvasive Imaging of $\hat{l}\pm\hat{Vl^2}$ 3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of Dasatinib. Cancer Research, 2009, 69, 3173-3179.	0.9	48
28	Imaging of integrin $\hat{l}\pm v\hat{l}^2$ 3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro-Oncology, 2009, 11, 861-870.	1.2	180
29	Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Frontiers in Bioscience - Landmark, 2009, Volume, 872.	3.0	73
30	68Ga- and 111 In-labelled DOTA-RGD peptides for imaging of $\hat{l}\pm v\hat{l}^2$ 3 integrin expression. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1507-1515.	6.4	145
31	Radionuclide Imaging. Journal of the American College of Cardiology, 2008, 52, 1-12.	2.8	855
32	Noninvasive Tracer Techniques to Characterize Angiogenesis. Handbook of Experimental Pharmacology, 2008, , 323-339.	1.8	7
33	A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nuclear Medicine Communications, 2007, 28, 870-875.	1.1	107
34	[18F]Galacto-RGD Positron Emission Tomography for Imaging of $\hat{l}\pm\nu\hat{l}^23$ Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2007, 13, 6610-6616.	7.0	217
35	3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranosyl Phenylthiosulfonate:  A Thiol-Reactive Agent for the Chemoselective 18F-Glycosylation of Peptides. Bioconjugate Chemistry, 2007, 18, 254-262.	3.6	63
36	[99mTc]HYNIC-RGD for imaging integrin αvβ3 expression. Nuclear Medicine and Biology, 2006, 33, 945-952.	0.6	114

#	Article	IF	CITATIONS
37	$\hat{l}\pm v\hat{l}^2$ 3-integrin imaging: a new approach to characterise angiogenesis?. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 54-63.	6.4	139
38	Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin $\hat{l}\pm v\hat{l}^2$ 3 Expression in Man. Clinical Cancer Research, 2006, 12, 3942-3949.	7.0	337
39	PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. Journal of Nuclear Medicine, 2006, 47, 763-9.	5.0	109
40	Noninvasive Visualization of the Activated $\hat{l}\pm v\hat{l}^23$ Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD. PLoS Medicine, 2005, 2, e70.	8.4	443
41	Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. Journal of Nuclear Medicine, 2005, 46, 1333-41.	5.0	202
42	Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochimica Acta, 2004, 92, .	1.2	85
43	[18F]Galacto-RGD:Â Synthesis, Radiolabeling, Metabolic Stability, and Radiation Dose Estimates. Bioconjugate Chemistry, 2004, 15, 61-69.	3.6	299
44	Radiolabeled Tracers for Imaging of Tumor Angiogenesis and Evaluation of Anti-Angiogenic Therapies. Current Pharmaceutical Design, 2004, 10, 1439-1455.	1.9	165
45	Comparison of [18F]FHPG and [124/1251]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 721-729.	2.1	75
46	In vivo imaging of herpes simplex virus type 1 thymidine kinase gene expression: early kinetics of radiolabelled FIAU. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 283-291.	6.4	49
47	Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the $\hat{l}\pm\hat{v}\hat{l}^2$ 3 Integrin for a New Cancer Therapy. Angewandte Chemie International Edition in English, 1997, 36, 1374-1389.	4.4	408